Peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors carries significant risk of radiation nephropathy, but amino acid infusions and emerging protective strategies can reduce kidney damage.
Kidney reabsorptionKidneys filter and reabsorb radiolabeled peptides, causing radiation exposure that can lead to nephropathy
What the researchers found
PRRT causes radiation nephropathy through renal reabsorption of radiolabeled peptides, with current mitigation strategies including amino acid co-infusion, receptor saturation, and cleavable linker technology showing promise for kidney protection.
Why it matters
As PRRT becomes increasingly used for neuroendocrine tumors and other cancers, understanding and preventing kidney damage is essential for patient safety and expanding this effective peptide-based therapy to more patients.
How the study worked
Narrative review of PRRT physics, renal handling of radionuclides, nephropathy mechanisms, dose thresholds, and protective strategies, written for practicing nephrologists.
What this study cannot tell us
Narrative review without new data. Protective strategies vary in evidence level. Many emerging approaches are still preclinical. Individual patient risk prediction remains imprecise.
How to read the evidence
Comprehensive narrative review synthesizing clinical and preclinical evidence on PRRT nephrotoxicity and protective strategies.
When this study was published
Published in 2025, reflecting current clinical practice and emerging protective technologies for PRRT.
The bigger picture
PRRT represents one of the most successful clinical applications of peptide targeting in medicine. Managing its kidney side effects is crucial for the continued expansion of peptide-based precision oncology.
Questions still open
- Can emerging cleavable linker technology eliminate PRRT-related kidney damage entirely?
- What is the optimal dosing schedule to maximize tumor kill while minimizing kidney exposure?
- Should patients undergo PRRT with mild-to-moderate kidney disease, and at what adjusted doses?
Common questions
What is PRRT and how does it use peptides?
How can kidney damage from PRRT be prevented?
Read the original research
Peptide receptor radionuclide therapy: a new era of radiation nephropathy.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 41(2), 220-232
Citation
Das, Abhirami; Kendi, Ayse Tuba; Manohar, Sandhya. (2026). Peptide receptor radionuclide therapy: a new era of radiation nephropathy.. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 41(2), 220-232. https://doi.org/10.1093/ndt/gfaf121